Fass, Daniel M. http://orcid.org/0000-0003-0018-8093
Lewis, Michael C.
Ahmad, Rushdy
Szucs, Matthew J.
Zhang, Qiangge
Fleishman, Morgan
Wang, Dongqing
Kim, Myung Jong
Biag, Jonathan http://orcid.org/0000-0003-0891-9567
Carr, Steven A.
Scolnick, Edward M.
Premont, Richard T. http://orcid.org/0000-0002-8053-5026
Haggarty, Stephen J. http://orcid.org/0000-0002-7872-168X
Funding for this research was provided by:
Stanley Medical Research Institute
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH095088)
MGH Research Scholars Program
Article History
Received: 25 April 2018
Revised: 18 March 2022
Accepted: 29 March 2022
First Online: 3 May 2022
Competing interests
: SJH is a member of the SAB and equity holder of Psy Therapeutics, Frequency Therapeutics, Sensorium Therapeutics, 4 M Therapeutics, and Proximity Therapeutics; and has received speaking/consulting fees from AstraZeneca, Amgen, Merck, and Syros, and RBNC. DMF has received consulting fees from Psy Therapeutics. None of these entities were involved in the current study.